Amneal Pharmaceuticals Inc Ordinary Shares - Class A AMRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
-
Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm
-
Amneal, mAbxience Get FDA Approval For Two Biosimilars
-
FDA Clears Amneal Epinephrine Injection
-
Amneal Gets Tentative FDA Approval for Asthma Treatment
Trading Information
- Previous Close Price
- $17.25
- Day Range
- $16.83–17.31
- 52-Week Range
- $9.49–19.26
- Bid/Ask
- $16.85 / $17.20
- Shares Outstanding
- 348.30M
- Market Cap
- $5.88B
- Volume/Avg
- 688 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 21.65
- Price/Sales
- 1.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 8,500
- Website
- https://www.amneal.com
Valuation
|
Metric
|
AMRX
|
|---|---|
Price/Earnings (Normalized) | 21.65 |
Price/Book Value | 163.13 |
Price/Sales | 1.77 |
Price/Cash Flow | 8.56 |
Price/Earnings
AMRX
Financial Strength
|
Metric
|
AMRX
|
|---|---|
Quick Ratio | 1.37 |
Current Ratio | 2.20 |
Interest Coverage | 1.88 |
Quick Ratio
AMRX
Profitability
|
Metric
|
AMRX
|
|---|---|
Return on Assets (Normalized) | 8.63% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 18.68% |
Return on Assets
AMRX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|Qt<%JC&^ | LOCK|$%d& | $67B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|nJ#<#Hm& | LOCK|YQ>! | $43B | |||
| Haleon PLC ADR
HLN
| LOCK|^f#$&j | LOCK|N% | $40B | |||
| Zoetis Inc Class A
ZTS
| LOCK|J<Fp@?< | LOCK|p% | $30B | |||
| Viatris Inc
VTRS
| LOCK|K<vL$#D | LOCK|!qj | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|<#? | LOCK|Ld | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|Xb<w>! | LOCK|#< | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|NqmN@$ | LOCK|@c | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|sQkDF^ | LOCK|KpS!P | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|JPY<Cxm | LOCK|$! | $2B |
United States